Rudin, C. M., Pietanza, M. C., Bauer, T. M., Ready, N., Morgensztern, D., Glisson, B. S., . . . Spigel, D. R. (2016). Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: A first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol.
Chicago Style CitationRudin, Charles M., et al. "Rovalpituzumab Tesirine, a DLL3-targeted Antibody-drug Conjugate, in Recurrent Small-cell Lung Cancer: A First-in-human, First-in-class, Open-label, Phase 1 Study." Lancet Oncol 2016.
MLA CitationRudin, Charles M., et al. "Rovalpituzumab Tesirine, a DLL3-targeted Antibody-drug Conjugate, in Recurrent Small-cell Lung Cancer: A First-in-human, First-in-class, Open-label, Phase 1 Study." Lancet Oncol 2016.